Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lupus drug may harm ovaries – could a hormone shot help?

NCT ID NCT05567198

Recruiting now Knowledge-focused Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 5 times

Summary

This study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who got GnRHa and those who did not, using questionnaires and medical records. The goal is to see if GnRHa really helps preserve ovarian function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
gonadotropin-releasing hormone agonist (GnRHa)
What this could lead to
If it works, this could point toward a way to preserve fertility in women with lupus who need cyclophosphamide.
What could go wrong
This is an observational survey, not a treatment trial. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY OVARIAN INSUFFICIENCY (POI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nephritis systemic lupus erythematosus primary ovarian failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY OVARIAN INSUFFICIENCY (POI) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.